Sales Ended

Hepatitis C Patient Input Webinar: SOF/VEL/VOX

Event Information

Share this event

Date and Time

Event description


Patient input is a cornerstone of CTAC’s work and ensures that the voices of people living with HIV and hepatitis C are heard by the Canadian Drug Expert Committee, which makes recommendations to public drug plans regarding the listings on their formularies as part of the Canadian Agency for Drugs and Technologies In Health (CADTH) Common Drug Review (CDR) process

As a valued member of CTAC, we consider you a leader in HIV and HIV/hepatitis C patient experience and would be like to invite you to take part in today's patient input session, a webinar where policy researcher Amanda Fletcher will be discussing the new hepatitis C treatment, sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX). We want feedback from members who are HCV treatment experienced.

This hepatitis C medication is pan-genotypic and has been researched as an option for various patient populations including people living with HIV/HCV co-infection, people with past treatment failure, people living with cirrhosis and people who have had liver or renal transplants.

This informative webinar will discuss the clinical trials supporting this new drug's examination by Canada's Common Drug Review. Participants will be offered an opportunity to communicate their opinion, which will be sent to the Canadian Drug Expert Committee for their consideration. Audio for this webinar will be played over your computer.

Don't delay. Register now! Please disseminate broadly within your networks.

On the day of the event, you will need to log on to the webinar at

Date and Time

Save This Event

Event Saved